BRCA Mutations Treatment Market - Top Companies and Manufacturers

Companies Dominating the BRCA Mutations Treatment Market

A number of end-use companies are available that deal with BRCA mutation treatment. Here are some majorities of key players;

Roche Holding AG

Company Overview
Business Planning
Main Product Offerings
Financial Execution
Main Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis

Celgene
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Pfizer Inc.
AstraZeneca
Merck & Co., Inc.
Novartis AG
AbbVie Inc.
Astellas Pharma Inc.

Browse Key Market Insights with Data Illustration:

BRCA Mutations Treatment Market Size & Share, Forecast Report 2036

In the News

Roche Holding AG, declared the U.S. Food and Drug Administration (FDA) acceptance of the cobas Malaria test for utilization on the cobas® 6800/8800 Systems. This accepted test can help healthcare professionals in limiting the possible risks of patient infection from imbued blood materials. The cobas Malaria test gives a highly sensitive and particular solution to assist confirm that infected blood units are eliminated from the blood supply.

Roche Holding AG, declared that the U.S. Food and Drug Administration (FDA) has accepted Xolair (omalizumab) for the limitation of allergic answers, comprising anaphylaxis, that may appear with accidental involvement in one or more foods in adults and pediatric patients aged 1 year and older with IgE-intervened food allergy.

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of BRCA mutation treatment was over USD 13 billion.

The market size for BRCA mutations treatment is projected to cross USD 23 billion by the end of 2036 expanding at a CAGR of 3% during the forecast period i.e., between 2024-2036.

The major players in the market are Roche Holding AG, Celgene, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Pfizer Inc., AstraZeneca, Merck & Co., Inc., Novartis AG, AbbVie Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company, Otsuka Holdings Co Ltd, Eisai Co Ltd, Shionogi & Co Ltd, and others.

In terms of type, the chemotherapy segment is anticipated to account for the largest market share of 68% during 2024-2036.

The North American BRCA mutation treatment sector is poised to hold the highest share of 39% by 2036.

BRCA Mutations Treatment Market - Top Companies and Manufacturers

Companies Dominating the BRCA Mutations Treatment Market

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the BRCA mutations treatment industry?

What is the outlook for the BRCA mutations treatment market?

Who are the major players dominating the BRCA mutation treatment landscape?

Which type segment will capture the significant market share for BRCA mutation treatment by 2036?

Which region will provide more opportunities for the BRCA mutation treatment business shortly?